Acurx Pharmaceuticals, Inc. financial data

Symbol
ACXP on Nasdaq
Location
Staten Island, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 179% %
Debt-to-equity 67% % -33%
Return On Equity -216% % 51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,855,025 shares -87%
Common Stock, Shares, Outstanding 2,348,113 shares 176%
Entity Public Float $13,700,000 USD -55%
Common Stock, Value, Issued $2,348 USD 176%
Weighted Average Number of Shares Outstanding, Basic 1,498,793 shares 85%
Weighted Average Number of Shares Outstanding, Diluted 1,498,793 shares 85%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,834,506 USD -66%
General and Administrative Expense $6,257,477 USD -28%
Operating Income (Loss) $2,028,701 USD 28%
Net Income (Loss) Attributable to Parent $7,966,538 USD 44%
Earnings Per Share, Basic -5.32 USD/shares 70%
Earnings Per Share, Diluted -5.32 USD/shares 70%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $6,157,858 USD
Assets $7,689,535 USD 99%
Employee-related Liabilities, Current $39,011 USD -93%
Liabilities, Current $2,420,943 USD -25%
Liabilities $2,420,943 USD -25%
Retained Earnings (Accumulated Deficit) $75,288,494 USD -12%
Stockholders' Equity Attributable to Parent $5,268,592 USD 757%
Liabilities and Equity $7,689,535 USD 99%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,051,499 USD 33%
Net Cash Provided by (Used in) Financing Activities $2,988,673 USD -34%
Common Stock, Shares Authorized 250,000,000 shares 25%
Common Stock, Shares, Issued 2,348,113 shares 176%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $937,174 USD -35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,556,100 USD 104%
Deferred Tax Assets, Valuation Allowance $18,787,465 USD 15%
Deferred Tax Assets, Gross $18,787,465 USD 15%
Deferred Tax Assets, Operating Loss Carryforwards $10,470,168 USD 31%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $80,554,738 USD 19%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%